Organogenesis Holdings Inc.'s SEC filings document a regenerative medicine issuer with Class A common stock listed on the Nasdaq Capital Market. The filings cover operating and financial results for Advanced Wound Care and Surgical & Sports Medicine products, including furnished 8-K earnings releases that separate product revenue by market category.
The company's regulatory record also includes proxy materials for annual meeting matters, director elections, advisory voting items, board governance and compensation disclosures. Other filings address Regulation FD and material-event updates for ReNu clinical and regulatory matters, capital-structure details involving Class A common stock and Series A Convertible Preferred Stock voting mechanics, and risk and governance topics tied to its product portfolio.
Organogenesis Holdings Inc. Chief Financial Officer Francisco David reported four tax-withholding dispositions of Class A common stock on February 15, 2026, at $3.73 per share. After these transactions related to tax obligations, he directly owned 506,647 Class A shares.
Organogenesis Holdings Inc. Chief Operating Officer Patrick Bilbo reported several insider transactions involving Class A common stock. On February 15, 2026, he disposed of shares in four separate transactions coded “F,” which indicates shares were delivered to cover a tax liability or exercise price.
Across these tax-withholding dispositions, shares were transferred at a reported price of $3.73 per share. After the final transaction, Bilbo continued to directly own 884,648 shares of Class A common stock, reflecting a substantial remaining equity stake in the company.
Organogenesis Holdings Inc. vice president of strategy Robert Cavorsi reported three tax-withholding dispositions of Class A Common Stock tied to equity compensation. On February 15, 2026, he delivered 6,667, 5,549 and 5,442 shares at $3.73 per share to cover tax obligations, and continued to hold a substantial direct stake afterward.
Organogenesis Holdings Inc. reported insider tax-related share dispositions by Chief Administrative and Legal Officer Lori Freedman. On February 15, 2026, she executed four Form 4 code F transactions in Class A common stock, delivering 4,043, 24,428, 12,761 and 13,510 shares at $3.73 per share to cover tax liabilities. Following these non-open-market transactions, she held 791,717 shares directly.
Organogenesis Holdings Inc. President and CEO Gary S. Gillheeney reported several tax-related share dispositions of Class A Common Stock. On February 15, 2026, he delivered an aggregate of 271,406 shares at $3.73 per share to satisfy tax withholding obligations. Following these transactions, he directly owned 3,243,917 Class A Common shares.
Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow reported four tax-withholding dispositions of Class A common stock on February 15, 2026. The transactions, coded “F” and priced at $3.73 per share, were used to satisfy tax liabilities and left him with 628,418 shares held directly.
Organogenesis Holdings Inc. vice president of health policy Antonio S. Montecalvo reported four tax-withholding dispositions of Class A Common Stock on February 15, 2026. A total of 18,619 shares were delivered at $3.73 per share to cover tax obligations, leaving him with 178,061 directly owned shares.
Organogenesis Holdings Inc. received an amended Schedule 13G from institutional investor First Light Asset Management, LLC and its control person, Mathew P. Arens, reporting their current ownership in the company’s common stock.
The filing shows First Light Asset Management may be deemed to beneficially own 3,611,616 shares, representing 2.85% of Organogenesis’ common stock. Mathew P. Arens may be deemed to beneficially own 3,888,816 shares, or 3.06% of the class, including 231,000 shares he holds directly and additional shares through joint and advised accounts.
The reporting persons certify the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Organogenesis. Because each now reports ownership below 5% of the outstanding shares, the filing confirms they are no longer large (5%+) shareholders.
Organogenesis Holdings Inc. has a large shareholder group led by Soleus Capital reporting a significant passive stake. Through Soleus Capital Master Fund, L.P., the group beneficially owns 9,985,951 shares of common stock, representing 7.9% of the outstanding shares based on 126,912,142 shares outstanding as of October 30, 2025.
All reported shares are held directly by the Master Fund, with several Soleus-affiliated entities and Guy Levy listed because of their control roles. These parties expressly disclaim beneficial ownership outside their reporting obligations under U.S. securities law and certify the holdings were not acquired to change or influence control of Organogenesis.
Organogenesis Holdings Inc. reported an insider stock transaction by a company director. On 12/16/2025, the director sold 200,000 shares of Class A Common Stock in open-market trades at a weighted-average price of $5.1353 per share, with individual trade prices ranging from $5.10 to $5.24.
After this sale, the director directly beneficially owns 2,565,591 shares of Class A Common Stock. In addition, the director has indirect beneficial ownership through three trusts holding 918,680 shares, 7,928,570 shares, and 335,719 shares of Class A Common Stock, respectively.